StockNews.AI
OKYO
StockNews.AI
200 days

OKYO Pharma Announces Chairman and CEO Acquire Shares

1. CEO Gary S. Jacob purchased 10,000 shares at $1.04 each. 2. Executive Chairman Gabriele Cerrone bought 20,000 shares, raising his stake to 28.96%. 3. OKYO is focused on treating neuropathic corneal pain and dry eye disease. 4. Company is progressing with Phase 2 trials for its lead product OK-101.

M&A
-3.64%Current Return
VS
-0.53%S&P 500
$1.101/31 07:02 AM EDTEvent Start
$1.0602/03 07:16 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Insider buying typically indicates confidence in company prospects. Historical examples show insider purchases often precede price increases.

How important is it?

The involvement of key executives in share purchases signifies confidence, likely influencing market perception.

Why Short Term?

Recent insider transactions could boost investor sentiment soon. Similar past instances have led to quick gains.

Related Companies

OKYOAMGNAPLS
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share. We have also been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 20,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share. This brings the total shareholding of Mr. Cerrone to 9,871,570 shares which is 28.96% of issued share capital. About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also currently evaluating OK-101 to treat NCP patients in a Phase 2 trial. Enquiries:     OKYO Pharma LimitedGary S. Jacob, Chief Executive OfficerU.S. 917-497-7560   Business Development & Investor RelationsPaul Spencer+44 (0)20 7495 2379

Related News